This page lists ClinicalTrials.gov records that name HGH among their listed interventions. Titles, phases, and status are taken from the official registry. It is a research reference only. It is not medical advice, and it does not offer or recommend any product for human or veterinary use.
Search
Compound
All compounds
HGH
Phase
All phases
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Observational
Not applicable
Expanded access
Status
All statuses
No registered studies match that search or filter.
Not yet recruiting Phase 1 HGH
NCT ID NCT06558422
Sponsor Columbia University
Registry dates 2027-01-01 – 2029-02-28
Enrollment 36 registered participants
Locations United States
Conditions listed Insulin Resistance; Hyperinsulinemia; Metabolic Dysfunction Associated Steatotic Liver Disease; Non-Alcoholic Fatty Liver Disease +2 more Registry record on ClinicalTrials.gov
Not yet recruiting Phase 4 HGH
NCT ID NCT07481656
Sponsor Anhui Provincial Hospital
Registry dates 2026-04-10 – 2028-10-30
Enrollment 160 registered participants
Locations China
Conditions listed Acute Brain Injuries; Moderate to Severe Traumatic Brain Injury Registry record on ClinicalTrials.gov
Enrolling by invitation Not applicable EPO HGH HMG
NCT ID NCT07568574
Sponsor Enhanced Emirates Limited
Registry dates 2026-03-12 – 2033-03-01
Enrollment 60 registered participants
Locations United Arab Emirates
Conditions listed Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes Registry record on ClinicalTrials.gov
Recruiting Phase 3 HGH
NCT ID NCT07309562
Sponsor Xiamen Amoytop Biotech Co., Ltd.
Registry dates 2026-01-20 – 2028-05-07
Enrollment 141 registered participants
Locations China
Conditions listed Small for Gestational Age Registry record on ClinicalTrials.gov
Recruiting Phase 3 HGH
NCT ID NCT07221851
Sponsor Ascendis Pharma A/S
Registry dates 2025-12-12 – 2029-03
Enrollment 186 registered participants
Locations United States, France, Germany +4 more
Conditions listed Turner Syndrome; Short Stature Homeobox Gene Mutation; Idiopathic Short Stature; Small for Gestational Age at Delivery Registry record on ClinicalTrials.gov
Recruiting Not applicable HGH
NCT ID NCT07359625
Sponsor University of Aarhus
Registry dates 2025-12-02 – 2028-04
Enrollment 10 registered participants
Locations Denmark
Conditions listed Insulin Resistance; Obesity & Overweight; Energy Metabolism; Ketone Body Metabolism Registry record on ClinicalTrials.gov
Recruiting Phase 2 HGH
NCT ID NCT07260500
Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Registry dates 2025-11-11 – 2027-04-30
Enrollment 72 registered participants
Locations China
Conditions listed Short Stature Children Born Small for Gestational Age (SGA) Registry record on ClinicalTrials.gov
Recruiting Phase 1 HGH
NCT ID NCT07016802
Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Registry dates 2025-06-09 – 2026-11-25
Enrollment 64 registered participants
Locations China
Conditions listed Safety; Tolerability; Adult Growth Hormone Deficiency Registry record on ClinicalTrials.gov
Not yet recruiting Phase 1 HGH
NCT ID NCT06840691
Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Registry dates 2025-05 – 2025-09
Enrollment 87 registered participants
Locations China
Conditions listed Pediatric Growth Hormone Deficiency (PGHD) Registry record on ClinicalTrials.gov
Active, not recruiting Phase 2 HGH
NCT ID NCT06433557
Sponsor Ascendis Pharma Growth Disorders A/S
Registry dates 2024-07-26 – 2027-11
Enrollment 22 registered participants
Locations Denmark, Ireland, United Kingdom
Conditions listed Achondroplasia Registry record on ClinicalTrials.gov
Withdrawn Phase 1 HGH
NCT ID NCT06126354
Sponsor Columbia University
Registry dates 2024-07-01 – 2026-03-31
Enrollment 0 registered participants
Locations United States
Conditions listed Insulin Resistance; Prediabetic State; Non-Alcoholic Fatty Liver Disease; Overweight and Obesity Registry record on ClinicalTrials.gov
Completed Phase 1 HGH
NCT ID NCT06385145
Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Registry dates 2024-05-08 – 2025-03-26
Enrollment 16 registered participants
Locations China
Conditions listed Pediatric Growth Hormone Deficiency (PGHD) Registry record on ClinicalTrials.gov
Completed Phase 1 HGH
NCT ID NCT06331026
Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Registry dates 2024-04-09 – 2024-08-28
Enrollment 87 registered participants
Locations China
Conditions listed Pediatric Growth Hormone Deficiency (PGHD) Registry record on ClinicalTrials.gov
Completed Phase 1 HGH
NCT ID NCT06135155
Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Registry dates 2023-11-06 – 2024-03-18
Enrollment 48 registered participants
Locations China
Conditions listed Pediatric Growth Hormone Deficiency (PGHD) Registry record on ClinicalTrials.gov
Recruiting Observational HGH
NCT ID NCT06037473
Sponsor Beijing Children's Hospital
Registry dates 2023-08-01 – 2029-08-01
Enrollment 2,600 registered participants
Locations China
Conditions listed Growth Hormone Treatment; Growth Disorders Registry record on ClinicalTrials.gov
Unknown status Phase 2, Phase 3 HGH
NCT ID NCT05900661
Sponsor Beni-Suef University
Registry dates 2023-07-30 – 2023-09-30
Enrollment 300 registered participants
Locations Egypt
Conditions listed Poor Responders Registry record on ClinicalTrials.gov
Completed Observational HGH
NCT ID NCT06295341
Sponsor Istituto Auxologico Italiano
Registry dates 2023-05-10 – 2024-01-31
Enrollment 80 registered participants
Locations Italy
Conditions listed Short Stature; Short; Stature, Psychosocial Registry record on ClinicalTrials.gov
Recruiting Phase 4 HGH Liraglutide
NCT ID NCT05681299
Sponsor Columbia University
Registry dates 2023-05-01 – 2028-04-30
Enrollment 40 registered participants
Locations United States
Conditions listed Healthy; Growth Hormone Deficiency Registry record on ClinicalTrials.gov
Completed Not applicable HGH
NCT ID NCT06433375
Sponsor Al-Azhar University
Registry dates 2023-04-01 – 2025-04-01
Enrollment 28 registered participants
Locations Egypt
Conditions listed Growth Hormone; EndoSeal MTA; Periapical Pathosis Registry record on ClinicalTrials.gov
Recruiting Observational HGH
NCT ID NCT06110910
Sponsor Xiaoping Luo
Registry dates 2023-03-01 – 2027-12-31
Enrollment 10,000 registered participants
Locations China
Conditions listed Childhood Short Stature Registry record on ClinicalTrials.gov
Active, not recruiting Phase 2 HGH
NCT ID NCT05690386
Sponsor Ascendis Pharma Endocrinology Division A/S
Registry dates 2023-02-15 – 2027-12
Enrollment 48 registered participants
Locations United States
Conditions listed Turner Syndrome Registry record on ClinicalTrials.gov
Unknown status Early Phase 1 HGH
NCT ID NCT05660356
Sponsor University of Calgary
Registry dates 2023-02 – 2025-02
Enrollment 20 registered participants
Conditions listed Growth Hormone Treatment; Growth Hormone Deficiency; Concussion, Mild; Concussion Post Syndrome Registry record on ClinicalTrials.gov
Recruiting Phase 3 HGH
NCT ID NCT05447208
Sponsor ShangHai Ji Ai Genetics & IVF Institute
Registry dates 2022-08-01 – 2026-12-31
Enrollment 400 registered participants
Locations China
Conditions listed Preimplantation Genetic Testing; Growth Hormone; Age, Parental Registry record on ClinicalTrials.gov
Unknown status Observational HGH
NCT ID NCT05390073
Sponsor Cairo University
Registry dates 2022-05-25 – 2022-06-15
Enrollment 50 registered participants
Conditions listed Epidermolysis Bullosa Dystrophica Registry record on ClinicalTrials.gov
Completed Phase 3 HGH Results posted
NCT ID NCT05171855
Sponsor Ascendis Pharma Endocrinology Division A/S
Registry dates 2021-12-16 – 2024-12-23
Enrollment 220 registered participants
Locations United States, Armenia, Australia +18 more
Conditions listed Adult Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency Registry record on ClinicalTrials.gov